| |
ACE cohort
|
Heidelberg/Mannheim cohort
|
P value of difference
|
|---|
|
MCI patients (N)
|
142
|
40
| |
|
Metabolomics profiling tissue
|
CSF and plasma
|
CSF
| |
|
Age (SD) blood collection, years
|
71.94 (7.74)
|
68.85 (8.50)
|
0.042
|
|
Female (%)
|
74 (52%)
|
22 (55%)
|
0.747
|
|
Body mass index (SD)
|
26.46 (3.74)
|
25.85 (3.61)
|
0.353
|
|
Lipid-lowering medication user (%)
|
63 (44%)
|
11 (27%)
|
0.055
|
|
Amyloid-beta 42 in pg/mL (SD)
|
791.59 (337.36)
|
690.84 (397.13)
|
0.151
|
|
P-Tau in pg/mL (SD)
|
71.37 (37.30)
|
63.17 (29.96)
|
0.153
|
|
Total tau in pg/mL (SD)
|
478.82 (253.45)
|
380.95 (326.97)
|
0.124
|
|
MMSE
|
24.93 (4.07)
|
26.55 (2.51)
|
2.67 × 10−3
|
|
CDR
|
0.50 (0.06)
|
0.55 (0.15)
|
0.047
|
|
APOE genotype N (%)
|
|
APOE 44/34/24
|
50 (35%)
|
18 (45%)
| |
|
APOE 33
|
81 (57%)
|
18 (45%)
| |
|
APOE 22/23
|
11 (8%)
|
4 (10%)
| |
- Abbreviations: MCI mild cognitive impairment, SD standard deviation, CSF cerebrospinal fluid, MMSE the Mini-Mental State Examination, CDR clinical dementia rating, APOE apolipoprotein E gene
